Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Cyclosporine in Idiopathic Membranous Nephropathy
NCT01180036Phase 3Completed
- Sponsor
- Mayo Clinic
- Start
- Nov 2011
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of rituximab in idiopathic membranous nephropathy (IMN) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Remission Status at 24 Months. Started Nov 2011; status: completed.
02
Drugs
rituximab
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT01180036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01180036.